Rituximab Offlabel denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for rituximab offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denied This Rituximab Claim as Non-Formulary

A non-formulary denial means rituximab either does not appear on BCBS's drug formulary for your specific plan, or it appears only at a specialty tier that requires prior authorization or step-therapy before coverage is available. For off-label uses, insurers sometimes also exclude the drug from formulary coverage for indications other than those in the FDA label.

Non-formulary denials are appealable, especially when no formulary alternative is clinically appropriate for your specific condition. The key argument is medical necessity for this specific agent over any listed formulary alternative.

## Your Federal Appeal Rights

• Formulary exception: Most BCBS plans offer a formulary exception process before or alongside the standard internal appeal. Request a formulary exception in writing, asking for coverage at the applicable formulary tier.
• Internal appeal: Under ERISA §503 (job-based plans) or applicable state law, you have the right to a full-and-fair review of a formulary exclusion decision.
• External review: Under ACA §2719, an IRO can review whether the formulary exclusion (as applied to your case) violates your plan terms. The filing window is typically four months from the final internal denial.
• Expedited option: Available for urgent clinical situations.

## Documentation to Gather

1. Diagnosis confirmation — specialist notes and supporting diagnostic records for the specific condition being treated. 2. Formulary alternative assessment — your prescriber should review each formulary alternative for your condition and document, for each, why it is contraindicated, was previously tried without adequate response, or is otherwise clinically inappropriate for you specifically. The FDA-approved prescribing information for each alternative is the reference source for this assessment. 3. Prescriber medical-necessity letter — explicitly addressing why rituximab is required over any formulary option and citing the applicable specialty-society guideline organization. 4. Prior-treatment history — dates, agents, and documented outcomes for any formulary alternatives already tried. 5. Clinical severity documentation — chart evidence of disease activity or progression that supports urgency.

## Criteria-Mapping Structure

Obtain BCBS's formulary exception criteria (usually published in the plan's Evidence of Coverage or available by calling the pharmacy benefits line). Map each exception criterion to a specific chart finding or prescriber statement. If the denial letter cites a specific formulary policy number, request the full text of that policy so your appeal addresses each requirement directly.